The event will discuss current thinking on biomarkers, clinical outcome scales, and other endpoints to contextualize data that was recently presented at the International Congress of Parkinson’s ...
Detailed price information for Gain Therapeutics Inc (GANX-Q) from The Globe and Mail including charting and trades.
Long Interspersed Nuclear Element-1 (LINE-1 or L1) is the only active, self-copying genetic element in the human ...
BETHESDA, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
BETHESDA, Md. - Gain Therapeutics, Inc. (NASDAQ:GANX), a $69 million market cap biotech company currently trading at $1.92 per share, announced Monday that its lead drug candidate GT-02287 showed ...
Researchers have shown that parasites of the genus Leishmania require the protein TKUL to maintain infections of host cells. • Two enzymes in one molecule: TKUL has two infection-relevant enzyme ...
Long interspersed nuclear element-1 (LINE-1 or L1) is the only active, self-copying genetic element in the human ...
The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark ...
Edinburgh, Scotland-based start-up Trogenix has raised £70 million ($95 million) for a pipeline of therapies for hard-to-treat aggressive cancer, starting with glioblastoma.
The authors describe an interesting approach to studying the dynamics and function of membrane proteins in different lipid environments. The important findings have theoretical and practical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback